Evidence map›Paper›PMID 28018990›Full record

ArticleScience immunology2016

The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness.

Tuoqi Wu, Yun Ji, E Ashley Moseman, Haifeng C Xu, Monica Manglani, Martha Kirby, Stacie M Anderson, Robin Handon, Elizabeth Kenyon, Abdel Elkahloun and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 419 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
419citing papers in PubMed, 1 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

419 citing papers in PubMed, 1 synthesis or guideline pooled it, 623 citations in OpenAlex.

  1. Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. CD39 on CD8European journal of immunology · 2026
    Review
  9. ANKRD11 deficiency reprograms CD8Nature immunology · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Decoding T cell exhaustion in the tumour microenvironment.Experimental & molecular medicine · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

359 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Tuoqi WuNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Yun JiNational Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
E Ashley MosemanNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Haifeng C XuDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
Monica ManglaniNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Martha KirbyNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Stacie M AndersonNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Robin HandonNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Elizabeth KenyonNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Abdel ElkahlounNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Weiwei WuNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Philipp A LangDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
Luca GattinoniNational Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Dorian B McGavernNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Pamela L SchwartzbergNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health · USNational Human Genome Research Institute · USNational Institute of Neurological Disorders and Stroke · USHeinrich Heine University Düsseldorf · DENational Cancer Institute · US

Funding

Mechanisms Underlying Clearance of the Persistently Infected CNSZIANS003111 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI MCGAVERN, DORIAN · 2009 to 2025
$33.0M
Genetic and Biochemical Approaches to Tyrosine Kinase FunctionZIAHG000123 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI SCHWARTZBERG, PAMELA · 2009 to 2018
$20.8M
Intramural NIH HHS ZIA HG000123Intramural NIH HHS ZIA NS003111
6 · The paper itself

Abstract

During chronic viral infections and in cancer, T cells become dysfunctional, a state known as T cell exhaustion. Although it is well recognized that memory CD8 T cells account for the persistence of CD8 T cell immunity after acute infection, how exhausted T cells persist remains less clear. Using chronic infection with lymphocytic choriomeningitis virus clone 13 and tumor samples, we demonstrate that CD8 T cells differentiate into a less exhausted TCF1

Identifiers

PMID28018990
PMCPMC5179228
OpenAlexW2561322596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.